Background/Objectives: Epithelial basement membrane dystrophy (EBMD) is a common corneal dystrophy characterized by recurrent corneal erosions and visual impairments due to surface irregularities and opacities. This study aims to evaluate the effectiveness of alcohol-assisted delamination (ALD) of the corneal epithelium in patients with EBMD affecting the visual axis, who experience decreased vision quality due to higher-order aberrations (HOAs) and irregular astigmatism. Methods: Eleven eyes of nine patients (four males and five females) were treated with ALD, with a mean age of 51.3 ± 19.7 years. All patients underwent refraction, best-corrected visual acuity (BCVA) assessment, a comprehensive slit-lamp examination for EBMD pattern identification, anterior segment imaging with and without fluorescein, tear break-up time (BUT) testing, corneal topography, corneal aberrometry (Zernike coefficients ($Z_n^m$) were calculated for a 5.0 mm simulated pupil), and anterior segment optical coherence tomography preoperatively and at 1-day, 14-day, 1-month, 3-month, 6-month, and 12-month intervals. Results: All patients demonstrated improvements in BCVA and visual quality, ocular comfort, and BUT results. The mean root mean square (RMS) value of total corneal aberrations decreased from 1.72 ± 0.90 μm to 0.90 ± 0.62 μm, while the mean RMS value of HOAs reduced from 0.92 ± 0.48 μm to 0.53 ± 0.28 μm. Astigmatism and trefoil were the aberration components that exhibited the most significant reductions. Conclusions: Alcohol-assisted delamination of the corneal epithelium is a safe and effective treatment for central EBMD patients experiencing visual quality deterioration. Astigmatism and trefoil appear to be the primary aberrations contributing to visual disturbances in this patient population.

Purpose. The primary objective of this study is to evaluate the efficacy and safety profile of PreserFlo MicroShunt implantation in the medium‐ to long‐term follow‐up of patients with open‐angle glaucoma. The secondary objective is to analyze laser flare meter (LFM) values before and after PreserFlo MicroShunt implantation. Methods. This prospective, observational, longitudinal single‐center study included a total of 62 eyes from 54 patients. A subgroup of 27 eyes (26 patients) reached the 12‐month follow‐up. Success was defined based on three criteria: criterion A: IOP ≤21 mmHg and ≥20% reduction; criterion B: IOP ≤15 mmHg and ≥25% reduction; and criterion C: IOP ≤12 mmHg and ≥30% reduction. Success was further categorized as complete if achieved without IOP‐lowering medications and qualified if achieved with medication administration. Other aspects evaluated included the number of IOP‐lowering medications (baseline and postoperative), development of postoperative complications, 5‐FU injections or implant revision, and LFM values. Results. The 12‐month follow‐up group (27 patients) was composed by 50% males and had a mean age of 75.54 ± 9.98 years. Success rates at 12 months were as follows: 78% for criterion A, 56% for criterion B, and 26% for criterion C. Complete success, as defined by criterion A, was achieved by 67% of the patients, 29% achieved qualified success, and one eye (4%) experienced failure. IOP decreased from 25.26 ± 1.67 mmHg at baseline to 14.81 ± 0.74 mmHg at 12 months. The number of medications decreased from 3.67 ± 1.30 at baseline to 0.48 ± 0.75 at 12 months. Reported complications were choroidal detachment (11%), hyphema (5%), and athalamia (flat anterior chamber) (2%) 13 eyes (48%) received 5‐FU injections, while 7 eyes (26%) underwent implant revision. No significant increase in LFM values was observed. Eyes with a regular postoperative course and IOP ≤15 mmHg showed significantly lower LFM values than patients with unfavorable outcomes (IOP >15 mmHg, development of complications, 5‐FU injection, or implant revision). Conclusions. PreserFlo MicroShunt showed a significant reduction in IOP and a decrease in the number of IOP‐lowering medications. Complications occurred at a modest frequency. The implant provides a minimally invasive approach with no significant increases in LFM values postoperatively. Higher LFM values correlate with unfavorable postoperative outcomes.

The epidemiology of uveitis remains highly variable, influenced by geographic location, genetic predisposition, environmental conditions, and socioeconomic context leading to significant differences in the distribution of clinical forms. The aim of this report was to analyse the epidemiological profile of uveitis at the tertiary referral center in Italy, providing a comprehensive overview of prevalence, clinical classifications, and etiological diagnoses. A retrospective study had been performed in a reference uveitis center in Italy, collecting data from February 2019 to December 2024. Demographic data, aetiology diagnosis and clinical characteristic were reported. Study enrolled 752 patients with ocular inflammation, 623 of whom had uveitis. Female represented the 58.51%, while the majority of patients were Caucasian (92.15%). Mean age was 51 years with middle-aged group represented the 68.75%. Noninfectious, including idiopathic forms, was the main aetiology (77.13%), followed by infectious (22.87%). Anterior uveitis (AU) was the 56.34%, posterior uveitis the 26.48%, panuveitis 11.57% and intermediate (IU) 5.61%. A statistically significant association was found between the aetiology and the localization (p < 0.0001). Herpetic infectious, HLA-B27-related, Fuchs, Toxoplasma and Sarcoidosis represented the main diagnosis. The study documented the epidemiology trend of uveitis, comparing with other European studies. Females and middle-aged group were the most frequent involvement groups. Noninfectious disease represented the primary etiologic cause. The AU was the main localization of inflammation. These results contribute to a better understanding of the distribution of uveitis in the region and help improve diagnostic and therapeutic processes.

To describe a case of Preserflo MicroShunt implantation in both eyes of a patient with intraocular pressure (IOP) rise after receiving bilateral Descemet's stripping automated endothelial keratoplasty (DSAEK), with poor IOP control by medical treatment alone. A female patient, previously diagnosed with primary open-angle glaucoma (POAG) and Fuchs' corneal dystrophy in both eyes, developed bilateral bullous keratopathy in late 2021. The patient underwent combined DSAEK and cataract surgery in her right eye (RE) in December 2021 and in April 2022 in her left eye (LE). After the surgical procedures, we observed an IOP rise not controlled by medical treatment. Bilateral Preserflo MicroShunt implantation was chosen as the surgical option to reduce the IOP increase and was performed in June 2022 in the LE and in July 2022 in the RE. The Preserflo MicroShunt implantation was successful in reducing the IOP in both eyes after bilateral DSAEK without the need for any additional hypotonic medical treatment. We observed good positioning of the device and the maintenance of corneal graft transparency and adhesion in both eyes after a 6-month follow-up from the most recent procedure. Preserflo MicroShunt has the potential to be a safe and effective technique in cases of IOP increase after endothelial keratoplasty. Further investigations with larger patient samples are required to validate our findings. IOP elevation after corneal transplantation can pose a challenge in the postoperative period and may lead to the need for glaucoma surgery. Our report on a case of bilateral Preserflo implantation after DSAEK highlights the potential benefits of this relatively new glaucoma surgical technique in the management of these patients. Della Lena F, Boni N, Messina M, et al. Bilateral Preserflo MicroShunt Implantation after Descemet's Stripping Automated Endothelial Keratoplasty: A Case Report. J Curr Glaucoma Pract 2026;20(1):34–37.

The aim of the study was to analyze the epidemiological, clinical and imaging characteristics of patients with inflammatory exudative retinal detachment (ERD). This multicenter, retrospective, observational study enrolled patients with a diagnosis of an inflammatory ocular disease associated with ERD. In all patients a complete ophthalmological evaluation was performed, with best-corrected visual acuity (BCVA), automated refraction, slit lamp biomicroscopy, intraocular pressure (IOP), fundus examination, optic coherence tomography (OCT) scan, color fundus photography, fluorescein angiography (FA) and indocyanine green angiography (ICGA). ERD was located (posterior pole, peripheral retina or both) with imaging, and the presence or absence of subfoveal neuroepithelial detachment, retinal pigment epithelium (RPE) detachment, epiretinal membrane (ERM), and macular edema (ME) were documented. 130 patients were enrolled, with a mean age of 52.14 ± 20.69 years. The most representative diagnosis was Vogt-Koyanagi-Harada (VKH) disease (23.85%), followed by Sarcoidosis (16.15%), Tuberculosis (13.08%) and Posterior Scleritis (PS) (9.23%). The principal location of ERD in the 165 enrolled eyes was in the posterior pole. In VKH, ERD was located at the posterior pole in 45 eyes, with 85.71% of subfoveal neuroepithelial detachment and choroidal granulomas in 87.76% of eyes. In PS a posterior pole location of ERD was found in 66.67% of eyes, with 83.33% of subfoveal neuroepithelial detachment and no choroidal granulomas. ERD is most frequently associated with VKH disease and the predominant localization is at the posterior pole, which occurs in the setting of posterior uveitis, panuveitis, and/or scleritis.